Directory Category: Drug Discovery

London, UK, 18 April 2023, – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that it has signed a strategic collaboration agreement with Professor Chris Lordís lab at The Institute of Cancer Research, London. The collaboration will use NeoPhore’s proprietary small molecule inhibitors of DNA mismatch repair (‘MMR’) to investigate single agent activity against tumours with defined genetic backgrounds.

Cambridge, UK, 04 April 2023 – Mosaic Therapeutics, Ltd, (ëMosaicí, or ëthe Companyí) an oncology therapeutics company dedicated to resolving cancerís complexity to power new treatments for patients, today announced the close of its $28 million series A funding round. The Company also announces the appointment of former Novartis Oncology SVP Brian Gladsden as CEO. The investment in this round was raised from Syncona Investment Management, Ltd, and Cambridge Innovation Capital.

Oxford, UK, 1st February 2023: Orbit Discovery Limited (Orbit), a leader in the discovery of therapeutic peptide hits, today announced it has entered into a multi target Research Agreement with Endevica Bio Inc., (Endevica), a company dedicated to creating first-in-class therapeutics for cachexia caused by cancer and other chronic conditions, with its lead compound having proven safe and well-tolerated in its Phase 1 trials. The collaboration aims to accelerate Endevicaís development of advanced G-protein coupled receptor (GPCR)-targeting therapeutics on receptor sets both novel and complimentary to its lead compound.